SEC 13F Intelligence

Managers / Q4 2024 · view latest →

Sofinnova Investments, Inc.

CIK 0001631134 · 3000 Sand Hill Road, BUILDING 3-SUITE 150, Menlo Park, CA, 94025 · 650.681.8428

Reported Value
$1.4B
Q4 2024
Positions
61
Filings on Record
33
2019–present window
Filed
Feb 14, 2025
original filing

Summary

Sofinnova Investments, Inc. reported $1.4B in U.S.-listed holdings across 61 positions for Q4 2024.

Its largest position, NTRA, represents 17.9% of the portfolio.

Compared with Q3 2024, the fund opened 17 new positions and exited 15.

Portfolio Metrics

Turnover
+32.7%
vs prior filed quarter
Top-10 Concentration
+57.1%
share of reported value
Largest Position
+17.9%
Natera
New / Exited
17 / 15
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $803MQ4 ’18Q1 ’19: $1.0BQ2 ’19: $1.1BQ3 ’19: $1.1BQ4 ’19: $1.4BQ4 ’19Q1 ’20: $1.1BQ2 ’20: $1.6BQ3 ’20: $1.3BQ4 ’20: $1.7BQ4 ’20Q1 ’21: $1.7BQ2 ’21: $1.7BQ3 ’21: $1.7BQ4 ’21: $1.7BQ4 ’21Q1 ’22: $1.3BQ2 ’22: $1.2BQ3 ’22: $1.7BQ4 ’22: $1.7BQ4 ’22Q1 ’23: $1.6BQ2 ’23: $1.5BQ3 ’23: $1.6BQ4 ’23: $1.8BQ4 ’23Q1 ’24: $1.8BQ2 ’24: $1.8BQ3 ’24: $1.3BQ4 ’24: $1.4BQ4 ’24Q1 ’25: $1.5BQ2 ’25: $1.6BQ3 ’25: $1.8BQ4 ’25: $2.3BQ4 ’25Q1 ’26: $2.6Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 87.5%Other: 9.3%ADR: 3.1%
  • Common Stock · 87.5% · $1.2B
  • Other · 9.3% · $128M
  • ADR · 3.1% · $43M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
GILDGilead Sciences IncNEW+774.2K774.2K+$72M$72M
ABBVAbbVie IncNEW+359.4K359.4K+$64M$64M
SRPTSarepta Therapeutics IncNEW+428.8K428.8K+$52M$52M
SYKStryker CorporationNEW+116.0K116.0K+$42M$42M
ALNYAlnylam Pharmaceuticals IncNEW+110.2K110.2K+$26M$26M
Alkermes PlcNEW+894.3K894.3K+$26M$26M
DC4Dexcom IncNEW+290.2K290.2K+$23M$23M
GMEDGlobus Med IncNEW+244.7K244.7K+$20M$20M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2024

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1NTRANatera Inchistory →COM17.88%$245M1.55M
2VERAVera Therapeutics Inchistory →CL A8.61%$118M2.79M
3GILDGilead Sciences Inchistory →COM5.21%$72M774.2K
4ABBVAbbVie Inchistory →COM4.65%$64M359.4K
5Jazz Pharmaceuticals PLCSHS USD4.52%$62M504.2K
6SRPTSarepta Therapeutics Inchistory →COM3.80%$52M428.8K
7AVBPArrivent BioPharma Inchistory →COM3.29%$45M1.70M
8AZNNAstraZeneca PLChistory →SPONSORED ADR3.11%$43M651.3K
9SYKStryker Corporationhistory →COM3.04%$42M116.0K
10AXSMAxsome Therapeutics Inchistory →COM3.03%$42M491.7K
11REPLReplimune Group Inchistory →COM2.78%$38M3.15M
12INCYIncyte Corphistory →COM2.64%$36M524.3K
13RAPPRapport Therapeutics Inchistory →COM2.58%$35M2.00M
14SLNOEURSoleno Therapeutics Inchistory →COM2.48%$34M757.2K
15BSXBoston Scientific Corphistory →COM2.25%$31M346.6K
16IDYAIDEAYA Biosciences Inchistory →COM2.00%$27M1.07M
17ALNYAlnylam Pharmaceuticals Inchistory →COM1.89%$26M110.2K
18Alkermes PlcSHS1.87%$26M894.3K
19DYNDyne Therapeutics Inchistory →COM1.84%$25M1.07M
20DC4Dexcom Inchistory →COM1.64%$23M290.2K
21RYTMRhythm Pharmaceuticals Inchistory →COM1.62%$22M397.4K
22GMEDGlobus Med Inchistory →CL A1.47%$20M244.7K
23ISRGIntuitive Surgical Inchistory →COM1.44%$20M37.9K
24IM8NInsmed Inchistory →COM PAR $.011.29%$18M256.3K
25YMABUSDY-mAbs Therapeutics Inchistory →COM1.25%$17M2.19M
26YB4PSavara Inchistory →COM1.22%$17M5.47M
27JANXJanux Therapeutics Inchistory →COM0.99%$14M253.3K
28BIOABioAge Labs Inchistory →COM0.97%$13M2.30M
29Inozyme Pharma IncCOM0.86%$12M4.28M
30LLYEli Lilly & Cohistory →COM0.81%$11M14.4K
31EWTXEdgewise Therapeutics Inchistory →COM0.78%$11M402.8K
32Pharvaris N VCOM0.78%$11M560.7K
33Aerovate Therapeutics IncCOM0.73%$10M3.76M
34Inari Med IncCOM0.67%$9M180.5K
35SNDXSyndax Pharmaceuticals IncCOM0.63%$9M658.6K
36INBXInhibrx Biosciences IncCOM0.59%$8M527.2K
37IMNMImmunome IncCOM0.58%$8M746.8K
38COGTCogent Biosciences IncCOM0.47%$6M823.2K
39SP4PAchieve Life Sciences IncCOM0.33%$5M1.31M
40ERASErasca IncCOM0.33%$5M1.80M
41Establishment Labs Hldgs IncCOM0.32%$4M95.3K
42AVTRAvantor IncCOM0.31%$4M200.0K
43EWEdwards Lifesciences CorpCOM0.22%$3M40.0K
44EXKExact Sciences CorpCOM0.21%$3M52.0K
45Immatics N.VSHS0.18%$2M343.2K
46DHRDanaher CorporationCOM0.17%$2M10.0K
47NXTCEURNextcure IncCOM0.15%$2M2.67M
48ANABAnaptysBio IncCOM0.13%$2M132.9K
49KROSKeros Therapeutics IncCOM0.11%$2M95.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$2.6B75May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.3B60Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.8B62Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.6B63Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.5B65May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.4B61Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.3B62Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.8B64Aug 15, 2024RESTATEMENTchanges · EDGAR ↗
Q1 2024$1.8B74May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.8B64Feb 13, 202413F-HRchanges · EDGAR ↗
Q3 2023$1.6B69Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$1.5B55Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$1.6B53May 11, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.7B53Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.7B61Nov 8, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.2B61Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.3B64May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.7B72Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.7B70Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.7B67Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.7B64May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.7B69Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.3B157Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.6B186Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.1B150May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.4B135Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.1B167Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.1B163Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.0B164May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$803M137Feb 22, 2019RESTATEMENTchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.